GRPR and metastatic neoplasm: In patients with prostate cancer, there is very promising preliminary clinical data pointing to the use of radiolabeled gastrin-releasing peptide receptor (GRP-R) ligands for detecting metastatic disease and monitoring disease progression [3, 4].